author-photo

Jacob Aelion

University of Tennessee Health Science Center

35

Papers

1697

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

2020 The Lancet Respiratory Medicine
Show All
- Source
- Cite
- Save
Citations (80)
ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

2018 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (33)
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

2018 Rheumatology
Show All
- Source
- Cite
- Save
Citations (34)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

2018 The Lancet
Show All
- Source
- Cite
- Save
Citations (111)
AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

2018 Scandinavian Journal of Rheumatology
Show All
- Source
- Cite
- Save
Citations (24)
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

2018 Rheumatology
Show All
- Source
- Cite
- Save
Citations (18)
AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis

2018 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study

2017 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (105)
Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study

2017
Show All
- Source
- Cite
- Save
Citations (19)